PET
bone metastasis
metastatic prostate cancer
racial differences
Journal
The Prostate
ISSN: 1097-0045
Titre abrégé: Prostate
Pays: United States
ID NLM: 8101368
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
25
04
2023
received:
17
07
2022
accepted:
07
05
2023
pmc-release:
01
09
2024
medline:
24
7
2023
pubmed:
22
5
2023
entrez:
22
5
2023
Statut:
ppublish
Résumé
Bone is the most common site of metastases in men with prostate cancer. The objective of this study was to explore potential racial differences in the distribution of tumor metastases in the axial and appendicular skeleton. We conducted a retrospective review of patients with metastatic prostate cancer to the bone as detected by Forty men met the inclusion criteria with 17 (42%) identifying as African Americans and 23 (58%) identifying as non-African Americans. Most of the patients had axial (skull, ribcage, and spine) disease. The location and the number of lesions in the skeleton of metastatic prostate cancer patients with low disease burden were not different by race. In low-disease burden patients with metastatic prostate cancer, there were no overall differences by race in the location and number of lesions in axial or appendicular skeleton. Therefore, given equal access to molecular imaging, African Americans might derive similar benefits. Whether this holds true for patients with a higher disease burden or for other molecular imaging techniques is a topic for further study.
Sections du résumé
BACKGROUND
Bone is the most common site of metastases in men with prostate cancer. The objective of this study was to explore potential racial differences in the distribution of tumor metastases in the axial and appendicular skeleton.
METHODS
We conducted a retrospective review of patients with metastatic prostate cancer to the bone as detected by
RESULTS
Forty men met the inclusion criteria with 17 (42%) identifying as African Americans and 23 (58%) identifying as non-African Americans. Most of the patients had axial (skull, ribcage, and spine) disease. The location and the number of lesions in the skeleton of metastatic prostate cancer patients with low disease burden were not different by race.
CONCLUSIONS
In low-disease burden patients with metastatic prostate cancer, there were no overall differences by race in the location and number of lesions in axial or appendicular skeleton. Therefore, given equal access to molecular imaging, African Americans might derive similar benefits. Whether this holds true for patients with a higher disease burden or for other molecular imaging techniques is a topic for further study.
Identifiants
pubmed: 37211866
doi: 10.1002/pros.24578
pmc: PMC10524638
mid: NIHMS1902502
doi:
Substances chimiques
Sodium Fluoride
8ZYQ1474W7
Fluorine Radioisotopes
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1193-1200Subventions
Organisme : NCI NIH HHS
ID : P30 CA022453
Pays : United States
Organisme : NCI NIH HHS
ID : P30CA022453-40
Pays : United States
Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
J Nucl Med. 2010 Dec;51(12):1826-9
pubmed: 21078790
Radiographics. 2018 Jan-Feb;38(1):200-217
pubmed: 29320333
J Nucl Med. 2018 Nov;59(11):1665-1671
pubmed: 29602821
Eur Radiol. 2018 Aug;28(8):3151-3159
pubmed: 29294158
J Nucl Med. 2021 May 10;62(5):695-699
pubmed: 32978283
J Natl Cancer Inst. 2021 Jan 4;113(1):64-71
pubmed: 32432713
Am Soc Clin Oncol Educ Book. 2021 Mar;41:1-12
pubmed: 33979195
Cancer. 2017 Jun 15;123(12):2312-2319
pubmed: 28436011
Radiology. 2021 Apr;299(1):27-35
pubmed: 33560191
Phys Med Biol. 2014 Mar 21;59(6):1485-99
pubmed: 24594843
J Clin Oncol. 2019 Feb 10;37(5):403-410
pubmed: 30576268
World J Mens Health. 2022 Apr;40(2):217-227
pubmed: 35021294
Phys Med Biol. 2018 Nov 20;63(22):225018
pubmed: 30457117
Clin Genitourin Cancer. 2019 Aug;17(4):306-314
pubmed: 31221545
Semin Nucl Med. 2016 Nov;46(6):491-501
pubmed: 27825429
Semin Nucl Med. 2005 Apr;35(2):135-42
pubmed: 15765376
Nucl Med Commun. 2017 Apr;38(4):325-332
pubmed: 28230714
Asian J Androl. 2018 May-Jun;20(3):215-220
pubmed: 29553053
J Nucl Med. 2008 Jan;49(1):68-78
pubmed: 18077529
J Clin Oncol. 2020 Nov 1;38(31):3662-3671
pubmed: 32897830
BJU Int. 2021 Aug;128(2):127-130
pubmed: 34318983
J Nucl Med. 2015 Feb;56(2):222-8
pubmed: 25593113
J Clin Oncol. 2016 May 10;34(14):1652-9
pubmed: 26951312
N Engl J Med. 2015 Aug 20;373(8):737-46
pubmed: 26244877
JAMA Netw Open. 2022 Jan 4;5(1):e2142093
pubmed: 34985518
CA Cancer J Clin. 2023 Jan;73(1):17-48
pubmed: 36633525
Front Oncol. 2020 Jan 31;10:55
pubmed: 32083008
CA Cancer J Clin. 2022 May;72(3):202-229
pubmed: 35143040
Prostate Cancer Prostatic Dis. 2021 Sep;24(3):718-724
pubmed: 33479454
Urology. 2018 Jul;117:101-107
pubmed: 29656066
Prostate Cancer Prostatic Dis. 2022 Sep;25(3):397-402
pubmed: 34475523